A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma

A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma

Aim: To ascertain the maximum tolerated dose (MTD)/maximum feasible dose (MFD) of WP1066 and p-STAT3 target engagement within recurrent glioblastoma (GBM) patients. Patients & methods: In a first-in-human open-label, single-center, single-arm 3 + 3 design Phase I clinical trial, eight patients w...

Full description

Saved in:
Bibliographic Details
Main Authors: John de Groot, Martina Ott, Jun Wei, Cynthia Kassab, Dexing Fang, Hinda Najem, Barbara O'Brien, Shiao-Pei Weathers, Carlos Kamiya Matsouka, Nazanin K Majd, Rebecca A Harrison, Gregory N Fuller, Jason T Huse, James P Long, Raymond Sawaya, Ganesh Rao, Tobey J MacDonald, Waldemar Priebe, Michael DeCuypere, Amy B Heimberger
Format: Article
Language:English
Published: Taylor & Francis Group 2022-06-01
Series:CNS Oncology
Subjects:
glioblastoma
Phase I
STAT3 inhibitor
toxicity
Online Access:https://www.futuremedicine.com/doi/10.2217/cns-2022-0005
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.futuremedicine.com/doi/10.2217/cns-2022-0005

Similar Items